What is Liraglutide?

A once-daily GLP-1 receptor agonist peptide; sold as Victoza for type 2 diabetes and Saxenda for weight management.

Open the Liraglutide reconstitution calculator

Liraglutide in the library · Metabolic & Weight Peptides · Human Trials · What are peptides?

455 registered trials · 660 indexed papers · 1133 human / 52 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

A once-daily GLP-1 receptor agonist peptide; sold as Victoza for type 2 diabetes and Saxenda for weight management.

Type: GLP-1 receptor agonist peptide.

Human research

The registered human trials and peer-reviewed human studies linked below are listed from ClinicalTrials.gov and PubMed. A study is linked only when Liraglutide is one of its interventions, or is named in the study title or subject headings.

Listing a study does not mean it showed a benefit, and it is not medical advice.

Registered human trials (455)

TrialPhaseStatusYearEnrolled
The Evira Study: Additional Support During Obesity Treatmentrecruiting202640
Estimating the Impact of Obesity Medications on Clinical and Economic Outcomesenrolling by invitation2026125000
RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.Phase 4not yet recruiting2026120
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 DiabetesPhase 2recruiting202560
A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and OsteoarthritisPhase 2active not recruiting2025129
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)Phase 1recruiting202571
Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)Phase 2recruiting202550
Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic ControlPhase 4recruiting2025430
Liraglutide Treatment in Obese Infertile PCOS WomenPhase 4recruiting2025890
Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures AlonePhase 4not yet recruiting202572
Effect of Liraglutide in Obese Women With Polycystic Ovary SyndromePhase 3completed2024183
Use of Liraglutide in Children Aged 6 to 12 Years With Severe ObesityPhase 4active not recruiting202430
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory IssuesEARLY_Phase 1suspended202430
Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.completed2024300
Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor AgonistsPhase 4active not recruiting202460
Holding vs. Continuing Incretin-based Therapies Before Upper EndoscopyPhase 4completed202469
Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2DPhase 1completed202412
Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonistscompleted202410
Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac SurgeryPhase 3recruiting2024260
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 DiabetesPhase 3unknown2024510
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese SubjectsPhase 1unknown202444
LIROH - Liraglutide for Obesity in HIVPhase 4unknown202440
Effects of GH and Lirglutide on AgRPPhase 4recruiting202340
Pharmacological Treatment - An Overview of Its Role in Managing Childhood Obesitycompleted2023128
Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic SurgeryPhase 4completed2023100
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in AmericaPhase 4completed2023500
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKDrecruiting2023250
Anti-obesity Pharmacotherapy and Inflammationactive not recruiting202330
Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes MellitusPhase 1/Phase 2recruiting202315
A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 DiabetesPhase 1completed202332
Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver DiseasePhase 4unknown2023102
Obesity Treatment to Improve Diabetescompleted202360
Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and InfertilityPhase 3unknown2023188
Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitusunknown2023300
POSE2.0 With GLP-1 Agonist for Obesity Managementunknown202350
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetescompleted2022396
Outcome of Overweight AF Patients Following Ablation With a Potential Weight Loss Medication ( GOAL-AF )active not recruiting202229
Safety, Tolerability and Pharmacokinetics of Intraarticular 4P004 Single Dose in Patient With KL 2-4 Osteoarthritic KneePhase 1completed202234
Efficacy of Liraglutide Therapy in Patients With IPAAPhase 2terminated20228
The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot StudyEARLY_Phase 1unknown202250

Peer-reviewed studies (660)

PaperAuthorsJournalYearType
A multicenter real-world study on the safety and effectiveness of the glucagon-like peptide-1 receptor agonist (liraglutide) in adolescents with obesity in TaiwanChiu CF et al.Obesity research & clinical practice2026Observational Study
Effectiveness of Liraglutide in Patients With Obesity Who Are Early Non-Responders to Lifestyle Intervention: A Real-World StudyGilardini L et al.Journal of obesity2026Observational Study
Liraglutide and Βeta-Cell Function in Young Adults With Long-Standing Type 1 Diabetes and Residual C-Peptide: A Blinded, Randomized Controlled TrialCaballero-Corbalán J et al.Diabetes, obesity & metabolism2026Randomized Controlled Trial
Weight Loss-Dependent Changes in Body Composition and Bone Health in People With Obesity and Type 1 Diabetes Treated With Liraglutide, Semaglutide, or TirzepatideAl Ozairi E et al.Diabetes/metabolism research and reviews2026Observational Study
Comparative analysis of IDegLira versus insulin glargine in short-term intensive therapy for overweight or obese patients with type 2 diabetes mellitusSun Y et al.Endocrine2026Randomized Controlled Trial
Effects of exercise and liraglutide on vascular health and inflammation during weight loss maintenance: a prespecified secondary analysis of the S-LiTE trialSandsdal RM et al.Nature metabolism2026Randomized Controlled Trial
Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 DiabetesNeumiller JJ et al.American journal of kidney diseases : the official journal of the National Kidney Foundation2026Observational Study
Accounting for non-adherence: A re-analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results trialSørensen KK et al.Clinical trials (London, England)2026Randomized Controlled Trial
Combining GLP-1 Receptor Agonists and Health-Behaviour and Lifestyle Therapy Yields Higher Adherence and Reduces Session Needs for Successful Weight Management in Adolescence: An Observational Real-World Single-Center StudyLischka J et al.Pediatric obesity2026Observational Study
GLP-1 receptor agonist therapy before bariatric surgery: Effects on weight loss and body composition in clinical practiceGutiérrez-Medina S et al.Obesity research & clinical practice2026Observational Study
The Liraglutide Effects in Atrial Fibrillation (LEAF) StudyGoldberger JJ et al.JACC. Clinical electrophysiology2026Randomized Controlled Trial
Liraglutide and Recurrent Stroke by Baseline Insulin Resistance: A Post Hoc Analysis of the LAMP TrialLu L et al.Stroke2026Randomized Controlled Trial
Six-month effects of liraglutide and dapagliflozin on lipid profile, cardiovascular risk, and NT-proBNP levels in patients with metabolic dysfunction-associated steatotic liver diseaseCherniavskyi V et al.Wiadomosci lekarskie (Warsaw, Poland : 1960)2026Randomized Controlled Trial
Comparison of the Continuous Glucose Monitoring Profiles of Four Glucose-Lowering Medications in the GRADE Randomized TrialBergenstal RM et al.Diabetes care2026Randomized Controlled Trial
Exploratory Analysis of Liraglutide Effects on Obstructive Sleep Apnea and Health-Related Quality of Life in Individuals With Obesity and COPD: A Secondary Analysis of a Randomised Controlled TrialWolsing SK et al.Clinical obesity2026Observational Study
Muscle atrophy associated with glucagon-like Peptide-1 receptor agonists: A population-based observational studyKwan ATH et al.Clinical nutrition (Edinburgh, Scotland)2026Observational Study
Effect of Calorie Restricted Diet Versus Liraglutide on Intrapancreatic Fat Deposition in People With Obesity: A Pilot StudyCheng H et al.Obesity (Silver Spring, Md.)2026Observational Study
Preventive effect of liraglutide on postoperative delirium in elderly patients undergoing cardiac surgery: protocol for a single-centre, randomised, double-blind, placebo-controlled trialBai S et al.BMJ open2026Clinical Study
Comparative evaluation of liraglutide plus metformin combination therapy versus metformin monotherapy in patients with type 2 diabetes mellitus: A retrospective clinical studyMai TMedicine2026Observational Study
Effects of liraglutide treatment for 35-days on total and regional fat free, lean, and bone mass, and on the Myostatin-Activin-Follistatin-IGF-1 axes: a secondary analysis of a randomized placebo-controlled crossover studyGutierrez de Piñeres V et al.Diabetes research and clinical practice2026Randomized Controlled Trial
Medication Adherence in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)Gonzalez JS et al.Diabetes care2026Randomized Controlled Trial
Proteomic effects of short-term liraglutide vs. placebo in a blinded crossover RCT: Implications for efficacy, safety, and comparison with semaglutideStefanakis K et al.Metabolism: clinical and experimental2026Randomized Controlled Trial
Mental health changes after 4 months of weight loss treatment with the glucagon-like peptide-1 analogue liraglutide [amount hidden]Kuckuck S et al.Diabetes, obesity & metabolism2026Observational Study
Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)Kahn SE et al.Diabetes care2026Randomized Controlled Trial
Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trialEdison P et al.Nature medicine2026Randomized Controlled Trial
Effects of liraglutide treatment for 18 days on metabolic parameters, regional body composition and the myostatin-activin-follistatin-IGF-1 axis: Results from an exploratory, randomized, placebo-controlled, crossover studyGutierrez de Piñeres V et al.Diabetes, obesity & metabolism2026Randomized Controlled Trial
Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack With Type 2 Diabetes: The LAMP Randomized Clinical TrialZhu H et al.JAMA internal medicine2026Randomized Controlled Trial
GLP-1 RA Medication Associations With Hazardous Alcohol Drinking Reductions in Patients With Overweight or Obesity: A Prospective Observational StudyKing AC et al.Journal of addiction medicine2026Observational Study
Risk of Sight-Threatening Diabetic Retinopathy with Glucagon-Like Peptide-1 Receptor Agonist Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and ExenatideBarkmeier AJ et al.Ophthalmology. Retina2026Observational Study
Real-world cardiovascular effects of liraglutide: transportability analysis of the LEADER trialJosey K et al.medRxiv : the preprint server for health sciences2026Preprint

More cited research

Conditions researched

Related compounds

FAQ

What is Liraglutide?

A once-daily GLP-1 receptor agonist peptide; sold as Victoza for type 2 diabetes and Saxenda for weight management.

How many registered human trials study Liraglutide?

The PeptideWhiz trial index lists 455 registered trials for Liraglutide, the most recent from 2026.

How much published research exists on Liraglutide?

The PeptideWhiz paper index links 660 PubMed papers to Liraglutide; by study type, 1133 human and 52 animal studies.

Which conditions is Liraglutide researched for?

Atherosclerosis, cardiovascular disease & high blood pressure, Chronic and systemic inflammation, Cognition, focus & brain performance, Concussion, traumatic brain injury & stroke recovery, Delayed gastric emptying on GLP-1 medicines, Dementia, Alzheimer's & cognitive decline, Diabetic retinopathy and glaucoma, Fat loss, obesity & body recomposition, Fatty liver & elevated liver enzymes, Female fertility, Gallbladder and gallstones, Gut: IBD (Crohn's, colitis), leaky gut, IBS & ulcers, Heart repair: after heart attack, heart failure & enlarged heart, High cholesterol and statins, Immune system (general), Insulin resistance, prediabetes & type 2 diabetes, Kidney protection (CKD, diabetic kidney, lupus kidney), Low testosterone (without or alongside TRT), Lung health, asthma & COPD, Multiple sclerosis, Muscle gain, sarcopenia & building muscle after 40, Neuropathy and CRPS, Osteoarthritis, cartilage loss & avoiding joint replacement, Osteoporosis and bone density, Pancreatitis (after the acute phase), Parkinson's disease, PCOS, Post-surgical inflammation and surgery recovery, Pregnancy and breastfeeding: safety notes, Psoriasis and psoriatic arthritis, Sleep apnea (obstructive), Sleep problems (incl. insomnia on peptides).

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).

Reported dosing ranges from research